Understanding REMS in SPL
Understanding REMS in SPL

Recorded Wednesday, February 10th 3pm ET

Register to view our webinar discussing the long-awaited FDA Final Guidance on REMS and what it means for you.

Reed Tech experts Gary Saner and David Wilson discussed the new structured format requirements for REMS (Risk Evaluation Mitigation Strategy) to help you understand what the final guidance includes, what actions are required of you and the deadlines surrounding these activities. The speakers explained how this move to structured content will increase access and ease of use for all REMS content stakeholders including sponsors, FDA, Providers, prescribers and patients.

Who should attend this webinar?
Regulatory Affairs
Quality Assurance

Reed Tech is the provider of best-in-class information-based solutions and services to meet the needs of the life sciences industry, government agencies, and the intellectual property market. Our customers are located throughout the world and include a wide range of medical device manufacturers and pharmaceutical companies, the U.S. government, numerous Patent Authorities, and IP-driven companies and law firms. The corporate mission is to advance humanity by delivering better outcomes to the innovation community. Reed Tech is a LexisNexis company.

For more information: Pharma@ReedTech.com, +1-215-557-3010

View the Recording